| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 23 Jul 2024 | 23 Jul 2024 |
| Increase in the authorised share capital of company. | ||
| Board Meeting | 10 Jul 2024 | 10 Jul 2024 |
| Resignation of Mr. Mehul Patel from the post of Chief Financial Officer of the Company with effect from July 10, 2024, Appointment of Ms. Anar Jayesh Patel (DIN: 02588388 ), as Additional Director (Whole-time Director), liable to retire by rotation, designated as Executive Director for a period of 5 years with effect from July 10, 2024 to July 09, 2029 and appointment of Mr. Jitendra Somchand Shah ( DIN: 01609325), as an Additional Director categorized as Non - Executive Independent Director of the Company, for a term of 5 consecutive years w.e.f. July 10, 2024 to July 9 2029 | ||
| Board Meeting | 29 May 2024 | 18 May 2024 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve Pursuant to Regulation 29 read with other applicable Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on 29th May 2024 Wednesday at the Registered Office of the Company inter alia to consider and approve the following: - 1. To Consider Adopt and Approve Audited financial result for the quarter and financial year ended on 31st March 2024 2. Recommend final dividend to the members of the company for the financial year 2023-24 3. Any other business with the permission of Chairman. In terms of the Companys Code of Conduct for Prevention of Insider Trading the Trading Window for dealing in securities of the Company has been closed from 1ST April 2024 till the end of 48 hours after the declaration of the Financial Results of the Company for the quarter and financial year ended on March 31 2024. With Reference to the subject, the board of directors of the company has recommended the dividend of Rs. 1/- that is 10% per equity share of Rs. 10/- each for the financial year 2023-24. (As Per BSE Announcement dated on 29.05.2024) | ||
| Board Meeting | 25 Apr 2024 | 25 Apr 2024 |
| The Company is informing the exchange about allotment of bonus shares The Company has received approval from shareholders to issue bonus shares through postal ballot on April 03rd 2024 and the BSE In Principle approval received on 18th March, 2024 bearing letter no: LOD/Bonus/BN-IP/TT/1444/2023-24. The Board of Directors in their meeting held today has approved allotment of 3,28,40,958 shares having face value of Rs. 10/-(Rupees Ten Only) each in ratio of 3(Three) new Equity shares for every 1(One) Equity shares held by the shareholders as on record date i.e. 20th April, 2024. | ||
| Board Meeting | 6 Apr 2024 | 6 Apr 2024 |
| The Board of directors has April 20, 2024 as record date. | ||
| Board Meeting | 28 Mar 2024 | 16 Mar 2024 |
| Intimation of the independent directors meeting to be held on 28th March, 2024. Outcome of meeting of Independent Directors of the company. (As per BSE Announcement Dated on 28/03/2024) | ||
| Board Meeting | 29 Feb 2024 | 23 Feb 2024 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/02/2024 inter alia to consider and approve 1. To consider and approve the proposal for issuance of fully paid up bonus equity shares to the members of the Company subject to necessary approval; 2. To consider and approve the proposal of increase in the authorized share capital of the Company and subsequent alteration to the Memorandum of Association of the Company. if needed subject to necessary approval; 3. To consider and finalize the matters to be included in Notice of EGM/Postal Ballot including day Date Place & Time if required; Further in terms of the SEBI (Prohibition of Insider Trading) Reg. 2015 and in accordance with the Companys Code of Conduct for Prevention of Insider Trading the Trading Window for dealing in securities of the Company shall remain closed from 23rd February 2024 to 02nd March 2024 (both days inclusive) i.e. till 48 hours after the public announcement of outcome of Board meeting scheduled to be held on February 29 2024 for the designated employees of the Company. Company Has Informed The Exchange That The Board Of Directors At Its Meeting Held On February 29, 2024, Have Considered And Approved Bonus At The Ratio Of 3 : 1, i.e 3 Equity Shares For Every 1 Equity Shares Held. Company has increased its Authorized capital Company has proposed to changed its Article of Association Other agenda are attached herewith. The Company has informed the Stock exchange regarding Bonus issue and such other matter. (As per BSE Announcement Dated on 29/02/2024) | ||
| Board Meeting | 12 Feb 2024 | 3 Feb 2024 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve 1. Unaudited Financial Result for the quarter ended on December 31 2023 along with the Limited Review Report of the Auditor pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015. 2. Any other business with the permission of Chairman. With reference to above subject and in compliance with Regulation 33 and 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e., Monday February 12, 2024 at 04:30 p.m. and concluded on 05.30 p.m.: - 1. Considered, adopted and approved Unaudited Financial Results for the third quarter and nine months ended on 31 December, 2023 along with the Limited Review Report thereon. The copies of the aforesaid Financial Results along with the Limited Review Reports thereon are enclosed herewith.) 2. Reviewed the other business of the company. (As Per BSE Announcement dated on 12.02.2024) | ||
| Board Meeting | 16 Dec 2023 | 16 Dec 2023 |
| 1. Conversion of 1,26,265 Partly Paid-up Equity Shares into fully paid-up equity shares. 2. Forfeiture of 12,739 Partly Paid-up Equity Shares on which First and/or Second Call(s) money remains unpaid. Conversion of partly paid-up equity shares to fully paid-up equity shares. Forfeiture of 12739 partly paid-up equity shares on which first and/or second call money was remains unpaid. | ||
| Board Meeting | 25 Nov 2023 | 25 Nov 2023 |
| 1. Appointment of Ms. Pinki Nirmal Sagar (DIN: 08113318) as an additional Non-Executive Independent Director of the Company w.e.f. November 25, 2023 for a period of five years, subject to approval of shareholder of the as per Regulation 17(1C) of SEBI Listing Regulations. 2. Re-appointment of Ms. Bhoomiben Patel (DIN: 08316893) as an Independent Director of the Company for a second term of five (5) years with effect from January 16, 2024, subject to approval of the Shareholders of the Company. 3. Notice of Postal Ballot for seeking approval of shareholders of the company. 4. Appointment of Mrs. Rupal Patel, Practicing Company Secretary (C.P. 3803) as scrutinizer for postal ballot process through electronic mode to conduct the Postal Ballot / E-voting process in a fair and transparent manner. As attached | ||
| Board Meeting | 8 Nov 2023 | 27 Oct 2023 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve 1. Unaudited financial result for the quarter and half year ended on September 30 2023 along with the Limited Review Report of the Auditor pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015. 2. Any other business with the permission of Chairman. Dear Sir/Madam, With reference to above subject and in compliance with Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e., Wednesday, November 8, 2023 at 04:00 p.m. and concluded on 04:45 p.m. inter alia considered and approved the following: 1. Un-Audited Financial Results (UFR) for the second quarter and half year ended September 30, 2023, along with the Statutory Auditors Limited Review Report. 2. Reviewed the other Business of the Company. with reference to above mentioned subject we hereby submit the outcome of meeting for the unaudited financial result for the quarter ended september 30, 2023 (As Per BSE Announcement dated on 11.11.2023) | ||
| Board Meeting | 13 Oct 2023 | 13 Oct 2023 |
| The board of directors of the Company at its meeting held today i.e. on Friday, October 13, 2023, considered and approved sending of a Final Demand cum Forfeiture Notice for payment of First Call Money of ? 07.00 per partly-up Equity Share (comprising ? 3.50 towards face value and ? 3.50 towards securities premium) and Second & Final Call Money of ? 8.00 per partly-up Equity Share (comprising ? 4.00 towards face value and ? 4.00 towards securities premium) (Aggregating to ? 15.00 per share comprising ? 7.50 towards face value and ? 7.50 towards securities premium) to the shareholders who have failed to pay both the First and Second & final call money and payment of Second & Final Call Money of ? 8.00 per partly-up Equity Share (comprising ? 4.00 towards face value and ? 4.00 towards securities premium) to the shareholders who have failed to pay Second & Final Call Money only. Final Demand Notice for payment of First Call Money and/or Second & Final Call Money | ||
| Board Meeting | 6 Oct 2023 | 6 Oct 2023 |
| taken note on the resignation of Mr. Jivansingh Gangasingh Negi (DIN-01656455), Independent director of the company w.e.f. October 06, 2023. | ||
| Board Meeting | 16 Aug 2023 | 16 Aug 2023 |
| 1. Appointment of Mr. Dhruvin Shah and Ms. Sanskruti Patel as an Additional Executive Directors of the Company 2. Appointment of Mr. Jivansingh Negi and Mr. Sarjeevan Rathore as an Additional Independent Directors of the Company. 3. Taken note on the resignation of Mr. Sujay Jyotindra Mehta (, Executive Director and Mr. Rai Kavoorguthu Konark Independent Director of the 4. Reconstituted the Committees of the Company 5. Directors Report for the year ended on March 31, 2023, and adoption of Secretarial Audit Report for the year ended on March 31, 2023 6. Convening the 30th AGM of the shareholders of the Company at 11.30 a.m., on Friday, September 22, 2023 at the registered office of the company. 7. Register of Members & Share Transfer Books of the Company will remain close from September 16, 2023 to September 22, 2023. 8. Appointment of Mrs. Rupal Patel, Practicing Company Secretary as Scrutinizer of Remote E-voting as well as voting at the AGM Appointment of Directors on the board of the company with effect from August 16, 2023 | ||
| Board Meeting | 12 Aug 2023 | 3 Aug 2023 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2023 inter alia to consider and approve 1. Unaudited financial result for the quarter ended on June 30 2023 along with the Limited Review Report of the Auditor pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015. 2. Appointment of Mrs. Sonal Deepalbhai Gandhi (DIN: 07351479) as an Additional Independent Director of the Company in accordance with the section 161 of the Companies Act 2013. 3. Appointment of Mrs. Rupal Patel Practicing Company Secretary as a Secretarial Auditor of the Company. 4. Any other business with the permission of Chairman. 1. Unaudited Financial Results for the quarter ended on June 30, 2023 along with the Limited Review Report thereon. 2. Appointment of Mrs. Sonal Gandh (DIN: 07351479) as an additional Non-Executive Independent Director of the Company w.e.f. August 12, 2023 subject to approval of shareholder of the company in the ensuing Annual General Meeting. 3. Appointment of Mrs. Rupal Patel, Practicing Company Secretary, as a Secretarial Auditor of the company. 4. Taken note on the resignation of Mr. Ashvin Trived, Non-Executive Non-Independent Director of the Company w.e.f. 12th August, 2023. 5. Reconstituted the Committees of the Company 6. Amended the Policy for Determination of Materiality of Event/Information to align with the requirements of the amended SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Appointment of Mrs. Rupal Patel, Practicing Company Secretary as Secretarial Auditor of the company. (As per BSE Announcement Dated on 12/08/2023) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
